ArticleOncology letters2019
Prognostic value of serum IL-8 and IL-10 in patients with ovarian cancer undergoing chemotherapy.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.Gynecologic oncology · 2020Trial
- Exploratory Analysis of Plasma Angiotensin-Converting Enzyme 2 and Angiotensin Peptides as Candidate Discriminatory Signals in Breast Cancer: A Pilot Case-Control Study.Biomedicines · 2026Article
- Targeting Monocytes and Their Derivatives in Ovarian Cancer: Opportunities for Innovation in Prognosis and Therapy.Cancers · 2026Review
- Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications.Molecular biomedicine · 2025Review
- Advances of oncolytic vaccinia viruses armed with interleukin in tumor therapy.Frontiers in oncology · 2025Review
- The complex role of IL-10 in malignant ascites: a review.Cancer immunology, immunotherapy : CII · 2024Review
- Predict value of tumor markers combined with interleukins for therapeutic efficacy and prognosis in ovarian cancer patients.American journal of cancer research · 2024Article
- Analysis of CXCL8 and its receptors CXCR1/CXCR2 at the mRNA level in neoplastic tissue, as well as in serum and peritoneal fluid in patients with ovarian cance.Molecular medicine reports · 2022Article
- The senescence-associated secretory phenotype in ovarian cancer dissemination.American journal of physiology. Cell physiology · 2022Review
- Prognostic value of preoperative soluble interleukin 2 receptor α as a novel immune biomarker in epithelial ovarian cancer.Cancer immunology, immunotherapy : CII · 2022Article
- Comparing the Secretomes of Chemorefractory and Chemoresistant Ovarian Cancer Cell Populations.Cancers · 2022Review
- Article
- Characteristics of Selected Adipokines in Ascites and Blood of Ovarian Cancer Patients.Cancers · 2021Review
- The Clinical Importance of IL-6, IL-8, and TNF-α in Patients with Ovarian Carcinoma and Benign Cystic Lesions.Diagnostics (Basel, Switzerland) · 2021Article
- Review
- Interleukin‑8 released by cancer‑associated fibroblasts attenuates the autophagy and promotes the migration of ovarian cancer cells.International journal of oncology · 2021Article
- IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.Advances in experimental medicine and biology · 2021Review
- Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- UEG Week 2019 Poster Presentations.United European gastroenterology journal · 2019Article
- Dual Actions of Ketorolac in Metastatic Ovarian Cancer.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prognostic value of serum interleukin-8 (IL-8) and interleukin-10 (IL-10) in patients with ovarian cancer undergoing chemotherapy was evaluated. The clinical data of ovarian tumor patients in Yidu Central Hospital of Weifang treated from January 2012 to December 2014 was retrospectively analyzed, 92 cases of which were malignant group, 64 cases were benign group, and 58 healthy subjects were selected as control group. Serum expression levels of IL-8 and IL-10 of the three groups were detected by enzyme-linked immunosorbent assay. Serum expression levels of IL-8 and IL-10 in benign and malignant groups both were higher than those in healthy control group (P<0.001). Serum expression levels of IL-8 and IL-10 of patients with ovarian cancer at III+IV stage were higher than that at I+II stage (P<0.001). Serum expression levels of IL-8 and IL-10 of patients with malignant ovarian tumors before chemotherapy were higher than those after chemotherapy (P<0.001). Serum levels of IL-8 and IL-10 of patients with malignant ovarian tumors in stable condition after chemotherapy were lower than those with recurrence and metastasis after chemotherapy (P<0.001). The median of serum expression levels of IL-8 and IL-10 was divided into low expression group and high expression group. The survival time of patients in high serum IL-8 and IL-10 expression group was significantly shorter than that in serum IL-8 and IL-10 low expression group (P<0.05). The survival time was negatively correlated with the expression levels of IL-8 and IL-10. Serum expression levels of IL-8 and IL-10 are closely related to the stages and prognosis of ovarian cancer. IL-8 and IL-10 may be involved in the occurrence and development of ovarian cancer. There are certain reference values on the changes of IL-8 and IL-10 levels, which may reflect the biological behavior and prognosis of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.